Literature DB >> 21301357

Multidisciplinary management of early and locally advanced esophageal cancer.

Jussuf T Kaifi1, Niraj J Gusani, Yixing Jiang, Heath B Mackley, Charles E Dye, Abraham Mathew, Eric T Kimchi, Michael F Reed, Kevin F Staveley-O'Carroll.   

Abstract

Clinical management of esophageal cancer is a multidisciplinary challenge. Diagnosis is associated with a high mortality and approximately 40% of patients have locally advanced disease at clinical presentation. Surgery remains one of the fundamental parts of treatment, but multimodal approaches including chemotherapy and radiation are associated with improved outcomes. This comprehensive review addresses the multidisciplinary management of early and locally advanced esophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21301357     DOI: 10.1097/MCG.0b013e3182049949

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  11 in total

Review 1.  Personalized and targeted therapy of esophageal squamous cell carcinoma: an update.

Authors:  Yongjing Liu; Zhaohui Xiong; Andrea Beasley; Thomas D'Amico; Xiaoxin Luke Chen
Journal:  Ann N Y Acad Sci       Date:  2016-07-11       Impact factor: 5.691

2.  Impact of a multidisciplinary tumour board meeting for upper-GI malignancies on clinical decision making: a prospective cohort study.

Authors:  Pieter van Hagen; Manon C W Spaander; Ate van der Gaast; Caroline M van Rij; Hugo W Tilanus; J Jan B van Lanschot; Bas P L Wijnhoven
Journal:  Int J Clin Oncol       Date:  2011-12-23       Impact factor: 3.402

3.  Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery.

Authors:  Jingchuan Zhang; Dongxian Jiang; Xiaojing Li; Jing Lv; Liang Xie; Li Zheng; Paul R Gavine; Qin Hu; Yuan Shi; Lijie Tan; Di Ge; Songtao Xu; Leon Li; Lifang Zhu; Yingyong Hou; Qun Wang
Journal:  Lab Invest       Date:  2014-07-07       Impact factor: 5.662

4.  Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models.

Authors:  Xianhua Wu; Jingchuan Zhang; Ruheng Zhen; Jing Lv; Li Zheng; Xinying Su; Guanshan Zhu; Paul R Gavine; Songtao Xu; Shaohua Lu; Jun Hou; Yalan Liu; Chen Xu; Yunshan Tan; Liang Xie; Xiaolu Yin; Deming He; Qunsheng Ji; Yingyong Hou; Di Ge
Journal:  J Transl Med       Date:  2012-08-30       Impact factor: 5.531

5.  The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma.

Authors:  Dongxian Jiang; Xiaojing Li; Haixing Wang; Yuan Shi; Chen Xu; Shaohua Lu; Jie Huang; Yifan Xu; Haiying Zeng; Jieakesu Su; Yingyong Hou; Lijie Tan
Journal:  BMC Cancer       Date:  2015-05-08       Impact factor: 4.430

6.  Comparing treatment plan in all locations of esophageal cancer: volumetric modulated arc therapy versus intensity-modulated radiotherapy.

Authors:  Jang-Chun Lin; Jo-Ting Tsai; Chih-Chieh Chang; Yee-Min Jen; Ming-Hsien Li; Wei-Hsiu Liu
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

7.  Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis.

Authors:  Raghibul Hasan; Rinu Sharma; Anoop Saraya; Tushar K Chattopadhyay; Siddartha DattaGupta; Paul G Walfish; Shyam S Chauhan; Ranju Ralhan
Journal:  BMC Cancer       Date:  2014-01-02       Impact factor: 4.430

8.  Diagnostic application of PIK3CA mutation analysis in Chinese esophageal cancer patients.

Authors:  Zizhen Ming; Dongxian Jiang; Qin Hu; Xiaojing Li; Jie Huang; Yifan Xu; Yalan Liu; Chen Xu; Xiuguo Hua; Yingyong Hou
Journal:  Diagn Pathol       Date:  2014-08-09       Impact factor: 2.644

Review 9.  Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.

Authors:  Andrea Santarelli; Marco Mascitti; Lucio Lo Russo; Davide Sartini; Giuseppe Troiano; Monica Emanuelli; Lorenzo Lo Muzio
Journal:  Int J Mol Sci       Date:  2018-03-24       Impact factor: 5.923

10.  miR-671-5p Blocks The Progression Of Human Esophageal Squamous Cell Carcinoma By Suppressing FGFR2.

Authors:  Xiaoyan Li; Changjun Nie; Baoqing Tian; Xuan Tan; Wei Han; Jiakang Wang; Yuan Jin; Yadan Li; Xinyuan Guan; An Hong; Xiaojia Chen
Journal:  Int J Biol Sci       Date:  2019-07-21       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.